Effect of p53 Gene Transfer and Cisplatin in a Peritonitis Carcinomatosa Model with p53-Deficient Ovarian Cancer Cells

摘要: Abstract Objective. To determine whether combination treatment consisting of p53 gene transfer and cisplatin (CDDP) improves prognosis ovarian cancer patients with peritonitis carcinomatosa, we tried this therapy in a carcinomatosa model that developed. Methods. A human adenocarcinoma cell line, HRA, which has homozygous deletion the gene, was used. For transfection, used recombinant adenovirus carrying wild-type (AxCAp53). efficiency to transduce HRA cells, cells were infected AxCALacZ, transduced detected by β-galactosidase staining. The expression protein monitored Western blot analysis up 15 days after infection 50 MOI AxCAp53. effect AxCAp53 CDDP evaluated 3-(4, 5-dimethelthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay. Apoptotic assessed morphologically staining Hoechst 33258. study, severe combined immunodeficiency mice an intraperitoneal injection cells. Results. expressed at 24 h disappeared on 14th day. present vitro study showed transduction significantly enhanced sensitivity apoptotic index significant survival advantage observed compared single treatments. However, repetitious did not show long term. Conclusion. suggests is potentially useful as adjuvant therapeutic modality for although further needed improve long-term those patients.